Early Development Bioconjugate Services

Start De-Risking your Bioconjugate Development Early

The rapid emergence of novel bioconjugation technologies provides exciting opportunities for enhanced therapeutic profiles, but also renders the development and manufacturing of bioconjugates increasingly complex.

Lonza offers early-development services to assist customers with tailoring bioconjugate development specifically to therapeutic needs and to streamline process development and manufacturing. Customers benefit from an integrated platform combining selected state-of-the-art bioconjugation technologies, drug-linker synthesis, and protein expression with over a decade of experience in the manufacturing of clinical and commercial bioconjugates.

Key attributes of our services are early de-risking and optimization of your protein scaffold, and a toolbox of robust and scalable bioconjugation technologies that will ensure a seamless transition to clinical and commercial manufacturing.

Access Robust and Scalable State-Of-The-Art Technologies with Our Conjugation Toolbox

We have established a comprehensive toolbox comprised of state-of-the art conjugation methodologies that can be applied to build bioconjugates from various protein formats.

We closely work with selected partner companies to make innovative bioconjugation technology available to our customers. Each of the technologies is assessed in our labs for its robustness, scalability, and ease of transfer into GMP.

Reach out to us if you want to learn more about our conjugation toolbox or if you are a technology provider who is interested in making the technology available to various drug developers.

Learn more about the Lonza Bioconjugation Toolbox and our partners here.

The conjugation toolbox is complemented by payloads and other small molecule technologies and our protein design, optimization and expression services located in Cambridge, UK.

Bioconjugate Design & Lead Generation: Our Workflow to Realize your Drug Concept

• In a joint meeting with you, we’ll discuss overall bioconjugate architecture and conjugation approaches are discussed, considering both product requirements and feasibility for development.
• Initial runs are performed to establish the process on lab scale, optimize the most important parameters and testing analytical methods.
• A panel of bioconjugate variants can be generated for Proof-of-Concept studies (typical outputs: 10 – 20 mg per variant).
• Larger amounts can be generated, e.g. for animal studies, by running a first scale up to supply g-amounts of your bioconjugate.

De-Risk your Bioconjugate Development Journey to the Clinic

• With +70 projects from preclinical development to commercial scale manufacturing and +300 GMP batches per year, we are uniquely positioned to help you on your drug development journey.
• From the earliest development phase, manufacturability and facility fit are considered in order to avoid re-optimization and repetition.
• Reducing the number of interfaces and technology transfers, ultimately de-risks and streamlines the path to IND and commercialization.